Global Hashimoto’s Thyroiditis Drug Market, By Drug Type (Wearable Devices and Non-wearable Devices), By Features (Basic Sleep Tracking, Sleep Staging, Heart Rate Monitoring, Respiratory Monitoring, and Others), By End User (Hospitals, Sleep Centers, Home

Global Hashimoto’s Thyroiditis Drug Market, By Drug Type (Wearable Devices and Non-wearable Devices), By Features (Basic Sleep Tracking, Sleep Staging, Heart Rate Monitoring, Respiratory Monitoring, and Others), By End User (Hospitals, Sleep Centers, Home Care Settings, and Diagnostic Laboratories), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

The global Hashimoto’s thyroiditis drug market was valued at US$ 2.18 Bn in 2023 and is expected to reach US$ 3.40 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Figure 1. Global Hashimoto’s Thyroiditis Drug Market Share (%), by Region, 2023

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis, is a long-term autoimmune disease in which the thyroid gland is attacked by the body's immune system. Some of the major symptoms include goiter formation in the neck, fatigue, unexplained weight gain, and sensitivity to cold. It is one of the most common causes of hypothyroidism in the U.S., which it affecting about 14 million Americans and costs billions in treatment annually. A variety of drugs are being used for its management, such as levothyroxine, to replace thyroid hormones, corticosteroids to suppress the immune response, and other symptom management drugs. With increasing incidence rates and overall healthcare cost burden, the Hashimoto’s thyroiditis drug market is poised to grow significantly in the coming years.

Market Dynamics:

The Hashimoto’s thyroiditis drug market is driven by the rising prevalence of autoimmune diseases globally, growing geriatric population, increasing awareness about the condition, and its management. According to an article published in the National Center for Biotechnology Information (NCBI) in 2023, after age six, Hashimoto is the most common cause of hypothyroidism in the U.S. and in those areas of the world where iodine intake is adequate. Globally, the incidence is estimated to be 0.8 per 1,000 per year in men and 3.5 per 1,000 per year in women. However, lack of awareness in developing nations, high costs of biologic drugs, and social stigma continue to restrain the market growth. On the other hand, the development of targeted therapies, combination drug treatments and online disease communities have opened up opportunities for players in this space. The market is witnessing the rising adoption of oral medications over surgical interventions. Players are investing in R&D to develop novel formulations with improved efficacy and safety profiles.

Key Features of the Study:

• This report provides an in-depth analysis of the global Hashimoto’s thyroiditis drug market, and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Hashimoto’s thyroiditis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include AbbVie Inc., Merck & Co., Allergan., Amneal Pharmaceuticals., Lannett Company, Mylan Pharmaceuticals, Pfizer, Akorn Pharmaceuticals, Acella Pharmaceuticals, Jerome Stevens Pharmaceuticals, and other prominent players
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Hashimoto’s thyroiditis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Hashimoto’s thyroiditis drug market

Detailed Segmentation:

• By Drug Type
• Thyroid hormone replacement therapy
• Anti-inflammatory drugs
• Antithyroid medications
• Anti-cretin medications
• Beta-blockers
• Calcium channel blockers
• Others (Supplements and Others)
• By Route of Administration
• Oral
• Injections
• Topical
• By Dosage Form
• Tablets
• Capsules
• Softgels
• Creams
• Others (Ointments and Others)
• By End Users
• Hospitals
• Sleep Centers
• Home Care Settings
• Diagnostic Laboratories
• By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Top Companies in the Global Hashimoto’s Thyroiditis Drug Market
• AbbVie Inc.
• Merck & Co.
• Allergan
• Amneal Pharmaceuticals.
• Lannett Company
• Mylan Pharmaceuticals
• Pfizer
• Akorn Pharmaceuticals
• Acella Pharmaceuticals
• Jerome Stevens Pharmaceuticals
• Other Prominent Players